The following blood tests were obtained from a trauma patient with stable haemodynamic parameters on day 3 of ICU.
|
Parameter |
Patient |
Reference |
|
Haemoglobin |
63 g/L* |
130-175 |
|
Haematocrit |
0.22* |
0.40-0.52 |
|
MCV |
98 fL |
80-99 |
|
MCH |
29 pg |
27-33 |
|
Platelets |
496 x 109/L* |
150-400 |
|
WBC |
20.0 x 109/L* |
4-11 |
|
Neutrophils |
13.6 x 109/L * |
1.9-7.5 |
|
Lymphocytes |
2.2 x 109/L |
1.0-4.0 |
|
Meta/myelocytes |
1.3 x 109/L* |
0.0-0.06 |
|
Nucleated RBC |
0.1 x 109/L* |
|
|
Reticulocytes |
162 x 109/L* |
10-100 |
|
Fibrinogen |
4.3 g/L* |
1.5-4.0 |
|
Sodium |
142 mmol/L |
135-145 |
|
Potassium |
3.8 mmol/L |
3.5-5.2 |
|
Urea |
15.1 mmol/L* |
3.2-7.7 |
|
Creatinine |
115 µmol/L* |
50-110 |
|
Glucose |
9.6 mmol/L* |
3.5-7.7 |
|
Calcium |
2.0 mmol/L* |
2.2-2.6 |
|
Phosphate |
0.9 mmol/L |
0.8-1.5 |
|
Magnesium |
1.0 mmol/L |
0.6-1.2 |
|
Protein |
51 g/L* |
64-83 |
|
Albumin |
24 g/L* |
32-48 |
|
Bilirubin |
79 µmol/L* |
2-20 |
|
Bilirubin (conjugated) |
47 µmol/L* |
0-5 |
|
Alkaline Phosphatase |
58 U/L |
30-150 |
|
Gamma GT |
507 U/L* |
10-50 |
|
AST |
287 U/L* |
10-50 |
|
ALT |
101 U/L* |
0-40 |
|
LDH |
282 U/L* |
110-120 |
|
CRP |
139mg/L* |
<5 |
a) Outline and explain the key abnormalities (4 marks)
b) Discuss the additional investigations you would request to assess anaemia in this patient (3 marks)
c) Describe the management of anaemia in this patient (3 marks)
Syllabus topic/section: 2.1.11 Haematological and Oncological Intensive Care 2.1.13 Trauma Intensive Care
Discussion:
A structured approach was necessary here and answers that were poorly structured did not score as well. Candidates who did well noted the need for explanation of the key abnormalities, not simply an outline as directed in the stem. Similarly, part (b) called for a discussion of the additional investigations rather than simply providing a list.
Candidates are reminded to read the question carefully and with particular reference to the glossary terms to ensure they have the best opportunity to include the relevant information in their answers. The rubric is provided to aid the candidate's future study.
Rubric
|
Below standard |
At standard |
Above standard |
|
|
a) Outline and explain the key abnormalities (4 marks) |
Limited integration or no supporting explanation of key abnormalities (as per at standard) Stipulating anaemia without any classification of anaemia |
Integration and explanation to cover minimum of
Consider at standard mark for otherwise above standard answer which omits one of minimum at standard criteria |
As at standard PLUS Integration and explanation of all/majority of abnormalities
|
|
0-1.5 marks |
2.0-2.5 marks |
3.0-4.0 marks |
|
|
b) Discuss the additional investigations you would request to assess anaemia in this patient (3 marks) |
List without discussion Omission of one or more of key topics as per at standard |
General principles that might guide subsequent subspecialty discussions
|
As at standard PLUS Detailed explanation of appropriate tests to support and refute potential causes. Detailed investigations for haemolysis assessment |
|
Consider at standard mark if above standard answer and omission of Hb production |
|||
|
0-1 marks |
1.5 marks |
2.0-3.0 marks |
|
c) Describe the management of anaemia in this patient (3 marks) |
Poorly structured with generic (not specific to this case) anaemia management answer. Omission of one or more of the minimum criteria for at standard, noting the comments regarding discretion 0-1 marks |
Minimum should cover Stop loss
Remove precipitant
Hb replacement
Use discretion based on answers given in question “b” but broad principles of loss, replacement and some basic disease specific management is a minimum 1.5 marks |
As at standard PLUS Greater detail and some question specific rather than generic management AND Detailed disease specific management (when, why and how)
2.0-3.0 marks |
"Outline" and "explain" is a strange mixture of exam vocabulary terms, as surely "explain" alone would have been enough. And which abnormalities are "key", versus those which are non-key? The rubric offers some answers.
Without too much effort, we can see the patient is clearly haemolysing.
Judging by the rubric, this was all unnecessary, and the most important elements were:
This 69-word answer would have fit within the 4-mark timeframe and would have hopefully satisfied the pickiest of examiners. Contrary to the rubric, it would have been impossible for the candidates to discriminate between intravascular and extravascular haemolysis here, as this would require further investigations.
b)
"Discuss" here suggests that advantages, disadvantages and controversies were sought, which would have been hard to do in three minutes. In any case, the investigations for anaemia are largely uncontroversial. "Discuss" here probably meant "include your rationale for the investigations", which should probably have looked something like this:
c)
The management of this anaemia would have been dependent on the kind of anaemia you convinced yourself this was, on the basis of investigations in b). Some sort of broad answer to cover all possibilites would have had to look like this:
Zeerleder, S. "Autoimmune haemolytic anaemia-a practical guide to cope with a diagnostic and therapeutic challenge." Neth J Med 69.4 (2011): 177-84.
Gehrs, Bradley C., and Richard C. Friedberg. "Autoimmune hemolytic anemia."American journal of hematology 69.4 (2002): 258-271.
Birgens, Henrik, et al. "A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia." British journal of haematology 163.3 (2013): 393-399.
Lechner, Klaus, and Ulrich Jäger. "How I treat autoimmune hemolytic anemias in adults." Blood 116.11 (2010): 1831-1838.
Salama, A., and B. Mayer. "Diagnostic pitfalls of drug-induced immune hemolytic anemia." Immunohematology 30.2 (2014): 80-4.
Zantek, Nicole D., et al. "The direct antiglobulin test: a critical step in the evaluation of hemolysis." American journal of hematology 87.7 (2012): 707-709.
Ma, Kim, and Stephen Caplan. "Refractory IgG Warm Autoimmune Hemolytic Anemia Treated with Eculizumab: A Novel Application of Anticomplement Therapy." Case reports in hematology 2016 (2016).
Pignon, Jean‐Michel, Emmanuelle Poirson, and Henri Rochant. "Danazol in autoimmune haemolytic anaemia." British journal of haematology 83.2 (1993): 343-345.
Beutler, Ernest. "G6PD deficiency." Blood 84.11 (1994): 3613-3636.
Frank, Jennifer E. "Diagnosis and management of G6PD deficiency." American family physician 72.7 (2005): 1277-1282.
Howes, Rosalind E., et al. "G6PD deficiency prevalence and estimates of affected populations in malaria endemic countries: a geostatistical model-based map." PLoS medicine 9.11 (2012): e1001339.
Luzzatto, Lucio, and Elisa Seneca. "G6 PD deficiency: a classic example of pharmacogenetics with on‐going clinical implications." British journal of haematology 164.4 (2014): 469-480.
Clark, Byron B., Robert W. Morrissey, and Dorothy Blair. "Relation of methemoglobin to hemolysis." Blood 6.6 (1951): 532-543.
Ata, Fateen, et al. "Favism Induced Methemoglobinemia in G6DP Deficient Patients: Case Series and Review of Literature." Blood 136.1 (2020): 11-12.